All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
7 matching companies
Crystal Bio Solutions describes bioanalytical and biomarker services, biologics characterization and CMC analytics, and clinical pharmacology. Its website lists immunoassay, molecular, cell-based, and mass-spectrometry techniques. Scope and quality requirements should be confirmed for the specific study and site.
Certara offers model-informed drug-development services and biosimulation software. Its public portfolio includes Phoenix for PK/PD analysis and Simcyp for PBPK modeling, alongside development and regulatory support. Software availability does not establish a model's fitness for a particular decision.
Simulations Plus offers modeling and simulation software and consulting across discovery and development. Its public software portfolio includes GastroPlus, MonolixSuite, and QSP tools. Modeling choices and validation should follow the intended scientific question.
Allucent describes clinical pharmacology strategy, PK/PD, pharmacometrics, modeling, and simulation. Nuventra is part of Allucent and is not counted here as a separate independent provider.
Altasciences describes integrated PK, PD, TK, biostatistics, exposure-response, and model-informed approaches from nonclinical translation through early clinical development. Its page identifies collaboration with Certara for model-informed trial design.
ICON lists population PK, PK/PD, exposure-response modeling, trial simulation, first-in-human dose prediction, and formulation-related IVIVC. These are service disclosures, not independent evidence of success for an individual project.
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
Coverage expands from sourced records; this database does not claim all biopharma companies.
